Skip to main content
IntegraGen logo

IntegraGen — Investor Relations & Filings

Ticker · ALINT ISIN · FR0010908723 LEI · 969500CQD8K0BUIGDH55 PA Professional, scientific and technical activities
Open in API
Filings indexed 160 across all filing types
Latest filing 2019-07-11 Earnings Release
Country FR France
Listing PA ALINT

About IntegraGen

https://integragen.com/

IntegraGen, an OncoDNA company, specializes in translating molecular research into clinical practice, with a primary focus on cancer genomics and rare genetic diseases. The company provides comprehensive genomic services, including Next-Generation Sequencing (NGS) and advanced bioinformatics analysis, to academic researchers, biopharmaceutical companies, and clinical research organizations. Operating from a CLIA/CAP-certified laboratory, IntegraGen is a key genomics partner for oncology clinical trials. Its core mission involves identifying novel genetic biomarkers to develop and commercialize molecular diagnostic tests, delivering interpretable genomic data to advance both research and patient care.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is a "COMMUNIQUE DE PRESSE - DIFFUSION IMMEDIATE" (Press Release - Immediate Release) announcing the company's unaudited revenue for the first half of 2019 ("Chiffre d'affaires de 4,2 M€ au premier semestre 2019"). It provides key financial highlights, a breakdown of revenue by segment, and future outlook. This format, focusing on preliminary or key results for a specific period (H1 2019) before the full comprehensive report, aligns perfectly with the definition of an Earnings Release (ER). It is not the full comprehensive Interim Report (IR) nor the Annual Report (10-K). The document explicitly states that the full financial results for H1 2019 will be published later (September 23, 2019), confirming this is the initial announcement of results. H1 2019
2019-07-11 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Half-Year Liquidity Contract Balance) and reports the status of shares and cash held under a liquidity contract as of June 30, 2019. This type of report details the activity related to maintaining market liquidity, often involving share buybacks or stabilization efforts. While it is a periodic report, it is not a full Annual Report (10-K) or an Interim Report (IR) detailing comprehensive operational results. It specifically relates to the mechanics of share trading/liquidity management. The closest fit among the provided definitions is 'Transaction in Own Shares' (POS), as liquidity contracts are mechanisms used for managing the company's own shares in the market. Given the specific focus on the liquidity contract balance, POS is the most appropriate classification, although it is a specialized report related to share transactions.
2019-07-05 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE - DIFFUSION IMMEDIATE" and presents the "Résultats annuels 2018" (Annual Results 2018) for IntegraGen, including key financial highlights, a detailed income statement table, a balance sheet table, and management commentary on the full fiscal year ending December 31, 2018. This content structure strongly indicates a formal announcement of annual financial performance. Since the document is a press release announcing the results rather than the comprehensive, audited filing itself (like a 10-K), and it focuses on periodical financial results, the most appropriate classification is 'Earnings Release' (ER). Although it covers the full year, the format is that of an initial release, not the full regulatory 10-K filing. If it were a comprehensive report, '10-K' would be considered, but the 'COMMUNIQUE DE PRESSE' header points towards an initial announcement. FY 2018
2019-04-18 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 97% confidence The document is explicitly labeled as a "PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION" and announces a significant business event: the signing of a global licensing agreement between IntegraGen and Advanced Biological Laboratories (ABL) for the commercialization of the miRpredX™ test. This type of announcement, detailing strategic partnerships, licensing deals, or major commercial milestones, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER) or governance filings (like DEF 14A, DVA). It is a general corporate announcement regarding business operations and strategy. Since it is not a report itself, but a news release about a business development, the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it serves as a broad communication to the market about a material event.
2019-03-05 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Half-Year Balance Sheet of the Liquidity Contract) and reports the status of shares and cash held under a liquidity contract as of December 31, 2018. This type of regular, periodic disclosure related to market making or liquidity provision, often required by stock exchanges, does not fit neatly into the primary financial reporting categories (10-K, IR, ER). It is a specific regulatory or contractual disclosure. Given the options, it is a specialized announcement. Since it is a specific report about a financial arrangement (liquidity contract balance) and not a general earnings release, management discussion, or a standard regulatory filing like insider trading or major shareholding, the most appropriate category is the general 'Regulatory Filings' (RNS) as a fallback for specific, non-standard disclosures, or potentially 'CAP' if interpreted as a financing mechanism update, but RNS is safer for miscellaneous contractual reports. However, upon reviewing the definitions, 'RNS' is the general fallback. This document details the status of a liquidity contract, which is a specific financial arrangement, but it is not a standard report like an Annual Report or Interim Report. It is a specific contractual disclosure. Given the highly specific nature and the lack of a perfect fit, RNS (Regulatory Filings) is the best general category for non-standard, required disclosures.
2019-01-15 French
Communiqués au titre de l'obligation d'information permanente / Information sur chiffre d’affaires annuel
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE - DIFFUSION IMMEDIATE" and presents key financial highlights for the year 2018, including revenue (Chiffre d'affaires) and cash position (trésorerie). It explicitly states the figures are 'non audité' (unaudited) and provides a summary of performance, strategic updates (SeqOIA launch, software sales), and outlook. This format, focusing on key figures and immediate release, strongly indicates an Earnings Release (ER), which is the initial announcement of periodical financial results, rather than the comprehensive Interim Report (IR) or the full Annual Report (10-K). The length (5222 chars) is substantial but the content is summary-focused, fitting the ER definition. FY 2018
2019-01-09 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.